drugset / Trial / NCT03313960

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

NCT03313960

RandomizedParallel-groupOpen-labelTreatment

Summary

The A-One study is a prospective, randomized controlled trial evaluating the use of the One Drop \| Premium 'On Track' in combination with Afrezza treatment on the glycemic control, treatment adherence, social-cognitive barriers to adherence, and treatment satisfaction of people with Type 2 diabetes (T2D) and a hemoglobin A1c (A1c) \> 7.0% already prescribed an injectable rapid-acting insulin.

Timeline

Start
2017-10-05
Primary completion
2018-09-30
Completion
2019-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Protein / enzyme biologic Inhaled